Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis.

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Abstract Text:

Y Kageyama,M Takahashi,T Ichikawa,E Torikai,A Nagano,

OBJECTIVE:The aim of this study was to evaluate the effects of anti-TNF-alpha antibody, infliximab, on oxidative stress markers representing DNA damage, lipid peroxidation, and glycoxidation.METHODS:Twenty-three RA patients underwent infliximab treatment and were analyzed for 30 weeks. Six patients who experienced side effects and one patient who had a reduced efficacy of infliximab were discontinued the infliximab treatment at 30-54 weeks. Sixteen patients were analyzed for 54 weeks. The levels of serum total, urinary total, and free pentosidine, which is an advanced glycation end-product (AGE), and of urinary 15-Isoprostane F2t and 8-hydroxy-deoxy guanosine (8-OHdG) were determined at baseline and at 14, 30, and 54 weeks after initial treatment with infliximab. RESULTS:Serum total, urinary total, and free pentosidine levels were reduced at 54 weeks after initial infliximab treatment. Urinary 15-Isoprostane F2t and 8-OHdG levels were also reduced at 14, 30, and 54 weeks. Urinary 8-OHdG levels in RA patients correlated with CRP and the Disease Activity Score of 28 joints.CONCLUSION:In RA patients, infliximab plays an essential role as an anti-oxidative agent against AGE formation, oxidative DNA damage and lipid peroxydation.

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Publishing Authors By Initials

Y Kageyama,M Takahashi,T Ichikawa,E Torikai,A Nagano,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical and experimental rheumatology

VOLUME: 26

Page Numbers: 73-80

Journal Abbreviation: Clin. Exp. Rheumatol.

ISSN: 0392-856X

DAY: 10

MONTH: 03

YEAR: 2008

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8308521

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis.

AFFILIATION: Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Country: Italy

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Rheumatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis Related Publications

• Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.
• Design and synthesis of zinc-selective chelators for extracellular applications.
• Development of an iminocoumarin-based zinc sensor suitable for ratiometric fluorescence imaging of neuronal zinc.
• Duality of alpha-subunit of canine kidney sodium- and potassium-activated adenosinetriphophatase in electrophoresis.
• Effect of reducing agents on the solubilization of renal sodium and potassium dependent ATPase with detergent.
• Establishment of a short-term in vitro assay for mouse spermatogonial stem cells.
• Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis.
• Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis.
• Highly sensitive near-infrared fluorescent probes for nitric oxide and their application to isolated organs.
• Identification and characterization of the cis-elements regulating the rat AMOG (adhesion molecule on glia)/Na,K-ATPase beta 2 subunit gene.
• Inhibition of eukaryotic DNA polymerase-alpha by polydeoxynucleotides.
• Isolation and characterization of DNA polymerases from mature oocytes of the starfish, Asterina pectinifera.
• Mechanism of release of maternal messenger RNA induced by fertilization in sea urchin eggs.
• Metabolism of urea and glyoxylate, degradative products of purines in marine animals.
• Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis.
• Primary structure of the alpha-subunit of human Na,K-ATPase deduced from cDNA sequence.
• Reconstitution of endogenous DNA synthesis in isolated nuclei and template activity of chromatin with respect to mode of inhibition by aphidicolin.
• Selective photoinactivation of protein function through environment-sensitive switching of singlet oxygen generation by photosensitizer.
• Sequential changes of bone metabolism in normal and delayed union of the spine.
• The inhibitory mode of aphidicolin on DNA synthesis in NaCl-treated HeLa cell nuclei.
• The transmembrane segment of the human Na,K-ATPase beta-subunit acts as the membrane incorporation signal.
• Time-resolved long-lived luminescence imaging method employing luminescent lanthanide probes with a new microscopy system.
• Transcription factors positively and negatively regulating the Na,K-ATPase alpha 1 subunit gene.
• Upper and lower urinary tract infection caused by Klebsiella pneumoniae serotype K2 and CTX-M-15 -lactamase-producing serotype K1: a case report and characterization of serum killing resistance.
• [Basic and Clinical Aspects of Calcimimetics. Discovery and development of calcimimetics.]
• [Chemical biology: overview]
• [Development of fluorescent probes for nitric oxide]
• [Hemolysis after ascending and arch replacement of the aorta; report of a case]
• [Mechanism-based molecular design of highly selective peroxynitrite probe]
• [Not Available.]